Marco Ruella

Author PubWeight™ 8.15^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.	Blood	2014	1.64
2	Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.	J Clin Invest	2016	1.05
3	The aging effect of chemotherapy on cultured human mesenchymal stem cells.	Exp Hematol	2011	0.85
4	Pregnancy complications predict thrombotic events in young women with essential thrombocythemia.	Am J Hematol	2014	0.84
5	Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma.	Ann Hematol	2013	0.83
6	Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report.	Blood Coagul Fibrinolysis	2012	0.82
7	Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.	Cancer	2011	0.81
8	A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.	Br J Haematol	2014	0.77
9	Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM.	J Clin Oncol	2013	0.76
10	A short course of granulocyte-colony-stimulating factor to accelerate wound repair in patients undergoing surgery for sacrococcygeal pilonidal cyst: proof of concept.	Cytotherapy	2012	0.75